155 related articles for article (PubMed ID: 11151744)
1. Effects of metronidazole on midazolam metabolism in vitro and in vivo.
Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):555-9. PubMed ID: 11151744
[TBL] [Abstract][Full Text] [Related]
2. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
5. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Ibrahim A; Karim A; Feldman J; Kharasch E
Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
[TBL] [Abstract][Full Text] [Related]
6. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.
Andersen V; Pedersen N; Larsen NE; Sonne J; Larsen S
Br J Clin Pharmacol; 2002 Aug; 54(2):120-4. PubMed ID: 12207630
[TBL] [Abstract][Full Text] [Related]
7. Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
Backman JT; Olkkola KT; Neuvonen PJ
Clin Pharmacol Ther; 1996 Jan; 59(1):7-13. PubMed ID: 8549036
[TBL] [Abstract][Full Text] [Related]
8. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
9. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.
Palovaara S; Kivistö KT; Tapanainen P; Manninen P; Neuvonen PJ; Laine K
Br J Clin Pharmacol; 2000 Oct; 50(4):333-7. PubMed ID: 11012556
[TBL] [Abstract][Full Text] [Related]
10. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
11. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
12. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
Zdravkovic M; Olsen AK; Christiansen T; Schulz R; Taub ME; Thomsen MS; Rasmussen MH; Ilondo MM
Eur J Clin Pharmacol; 2003 Feb; 58(10):683-8. PubMed ID: 12610745
[TBL] [Abstract][Full Text] [Related]
13. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
14. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
15. Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.
Rogers JF; Nafziger AN; Kashuba AD; Streetman DS; Rocci ML; Choo EF; Wilkinson GR; Bertino JS
J Clin Pharmacol; 2002 Oct; 42(10):1079-82. PubMed ID: 12362920
[TBL] [Abstract][Full Text] [Related]
16. A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects.
Urva S; Bouillaud E; Delaney R; Jappe A; Cheung W
J Clin Pharmacol; 2013 Apr; 53(4):444-50. PubMed ID: 23426978
[TBL] [Abstract][Full Text] [Related]
17. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
18. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
[TBL] [Abstract][Full Text] [Related]
19. Interaction between fluconazole and midazolam in intensive care patients.
Ahonen J; Olkkola KT; Takala A; Neuvonen PJ
Acta Anaesthesiol Scand; 1999 May; 43(5):509-14. PubMed ID: 10341997
[TBL] [Abstract][Full Text] [Related]
20. Azithromycin does not increase plasma concentrations of oral midazolam.
Backman JT; Olkkola KT; Neuvonen PJ
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):356-9. PubMed ID: 7582388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
